Floatz logo

Humax-Cd20

Leukaemia, Lymphocytic, Chronic

Emory Universitymonoclonal_antibodyPhase 4 / ApprovedDormant
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
95/ 100

Competitive context

72 Active assets in the Leukaemia, Lymphocytic, Chronic cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 4BBB
Acalabrutinib
Zulfa Omer
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Zulfa Omer
Phase 4BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 4BBB
Cediranib
City of Hope Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

Humax-Cd20 is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
67 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →